It makes sense and dollars to buy Grifols SA ADR (GRFS) stock

With 3.14 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.19 million shares. During the session, the Drug Manufacturers – General company that operates in wider Healthcare sector, reached to the highest price of $7.6893 whereas the lowest price it dropped to was $6.67. The 52-week range on GRFS shows that it touched its highest point at $12.15 and its lowest point at $5.30 during that stretch. It currently has a 1-year price target of $14.92. Beta for the stock currently stands at 0.57.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GRFS was up-trending over the past week, with a rise of 9.85%, but this was up by 14.22% over a month. Three-month performance dropped to -10.97% while six-month performance fell -16.16%. The stock lost -14.53% in the past year, while it has lost -35.38% so far this year. A look at the trailing 12-month EPS for GRFS yields 0.25 with Next year EPS estimates of 1.14. EPS is expected to grow by 32.40% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -37.97%.

Float and Shares Shorts:

At present, 256.91 million GRFS shares are outstanding with a float of 256.76 million shares on hand for trading. On 2024-04-30, short shares totaled 6.71 million, which was 99.00000000000001 higher than short shares on 1711584000. In addition to Mr. Thomas H. Glanzmann as the firm’s Executive Chairman, Mr. Jose Ignacio Abia Buenache serves as its CEO & Director.

Institutional Ownership:

Through their ownership of 0.47479 of GRFS’s outstanding shares, institutional investors have minority control over the company.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, GRFS reported revenue of $1769549000.0 and operating income of $86785000.0. The EBITDA in the recently reported quarter was $97005000.0 and diluted EPS was $nan.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for GRFS since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.